Is Tiziana Life Sciences Ltd (TLSA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 2.1% / 30% | 2.1% / 30% | N/A | ✓ HALAL |
| DJIM | 0.1% / 33% | 2.1% / 33% | 2.1% / 33% | N/A | ✓ HALAL |
| MSCI | 0.9% / 33% | 33.0% / 33% | 32.7% / 33% | N/A | ✓ HALAL |
| S&P | 0.1% / 33% | 2.1% / 33% | 2.1% / 33% | N/A | ✓ HALAL |
| FTSE | 0.9% / 33% | 33.0% / 33% | 32.7% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -232.3% | |
| Return on Assets (ROA) | -83.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$2M |
| Free Cash Flow | -$2M |
| Total Debt | $106,000 |
| Debt-to-Equity | 1.2 |
| Current Ratio | 1.7 |
| Total Assets | $11M |
Price & Trading
| Last Close | $1.25 |
| 50-Day MA | $1.41 |
| 200-Day MA | $1.69 |
| Avg Volume | 201K |
| Beta | 0.3 |
|
52-Week Range
$0.73
| |
About Tiziana Life Sciences Ltd (TLSA)
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Tiziana Life Sciences Ltd (TLSA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Tiziana Life Sciences Ltd is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Tiziana Life Sciences Ltd's debt ratio?
Tiziana Life Sciences Ltd's debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.9%.
What are Tiziana Life Sciences Ltd's key financial metrics?
Tiziana Life Sciences Ltd has a market capitalization of $158M. Return on equity stands at -232.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.